BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Salameh TS, Rhea EM, Talbot K, Banks WA. Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics. Biochem Pharmacol 2020;180:114187. [PMID: 32755557 DOI: 10.1016/j.bcp.2020.114187] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen S, Chuang Y, Lin T, Yang J. Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.175439] [Reference Citation Analysis]
2 Vergès B, Aboyans V, Angoulvant D, Boutouyrie P, Cariou B, Hyafil F, Mohammedi K, Amarenco P. Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms. Cardiovasc Diabetol 2022;21:242. [DOI: 10.1186/s12933-022-01686-3] [Reference Citation Analysis]
3 Cao Y, Yu F, Lyu Y, Lu X. Promising candidates from drug clinical trials: Implications for clinical treatment of Alzheimer's disease in China. Front Neurol 2022;13. [DOI: 10.3389/fneur.2022.1034243] [Reference Citation Analysis]
4 Zhang L, Li C, Zhang Z, Zhang Z, Jin Q, Li L, Hölscher C. DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce α-Synuclein Levels in the 6-OHDA Parkinson’s Disease Rat Model. Parkinson's Disease 2022;2022:1-11. [DOI: 10.1155/2022/1428817] [Reference Citation Analysis]
5 Ferrari F, Moretti A, Villa RF. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives. Pharmacology & Therapeutics 2022;239:108277. [DOI: 10.1016/j.pharmthera.2022.108277] [Reference Citation Analysis]
6 Kopp KO, Glotfelty EJ, Li Y, Greig NH. Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Neuroinflammation: Implications for Neurodegenerative Disease Treatment. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106550] [Reference Citation Analysis]
7 Nowell J, Blunt E, Edison P. Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease. Mol Psychiatry 2022. [PMID: 36258018 DOI: 10.1038/s41380-022-01792-4] [Reference Citation Analysis]
8 Reich N, Hölscher C. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review. Front Neurosci 2022;16:970925. [DOI: 10.3389/fnins.2022.970925] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Dong M, Wen S, Zhou L. The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors. Diabetes Metab Syndr Obes 2022;15:2583-97. [PMID: 36035518 DOI: 10.2147/DMSO.S375559] [Reference Citation Analysis]
10 Diz-chaves Y, Mastoor Z, Spuch C, González-matías LC, Mallo F. Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases. IJMS 2022;23:9583. [DOI: 10.3390/ijms23179583] [Reference Citation Analysis]
11 Gao S, Zhang Y, Liang K, Bi R, Du Y, Baiocchi M. Mesenchymal Stem Cells (MSCs): A Novel Therapy for Type 2 Diabetes. Stem Cells International 2022;2022:1-17. [DOI: 10.1155/2022/8637493] [Reference Citation Analysis]
12 Hölscher C. Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases. Front Synaptic Neurosci 2022;14:955258. [DOI: 10.3389/fnsyn.2022.955258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ogura J, Yamaguchi H. The Effectiveness of Antidiabetic Drugs in Treating Dementia: A Peek into Pharmacological and Pharmacokinetic Properties. Int J Mol Sci 2022;23:6542. [PMID: 35742986 DOI: 10.3390/ijms23126542] [Reference Citation Analysis]
14 Mahapatra MK, Karuppasamy M, Sahoo BM. Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review. Pharm Res 2022. [PMID: 35650449 DOI: 10.1007/s11095-022-03302-1] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Yang X, Feng P, Ji R, Ren Y, Wei W, Hölscher C. Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease. Expert Opin Ther Targets 2022. [PMID: 35584372 DOI: 10.1080/14728222.2022.2079492] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
16 González A, Calfío C, Churruca M, Maccioni RB. Glucose metabolism and AD: evidence for a potential diabetes type 3. Alzheimers Res Ther 2022;14:56. [PMID: 35443732 DOI: 10.1186/s13195-022-00996-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Cheng D, Yang S, Zhao X, Wang G. The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases. Drug Des Devel Ther 2022;16:665-84. [PMID: 35340338 DOI: 10.2147/DDDT.S348055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
18 Yang X, Qiang Q, Li N, Feng P, Wei W, Hölscher C. Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research. Front Neurol 2022;13:844697. [PMID: 35370875 DOI: 10.3389/fneur.2022.844697] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Shevchouk OT, Tufvesson-Alm M, Jerlhag E. An Overview of Appetite-Regulatory Peptides in Addiction Processes; From Bench to Bed Side. Front Neurosci 2021;15:774050. [PMID: 34955726 DOI: 10.3389/fnins.2021.774050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Liu XY, Zhang N, Zhang SX, Xu P. Potential new therapeutic target for Alzheimer's disease: Glucagon-like peptide-1. Eur J Neurosci 2021;54:7749-69. [PMID: 34676939 DOI: 10.1111/ejn.15502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Cai HY, Yang D, Qiao J, Yang JT, Wang ZJ, Wu MN, Qi JS, Hölscher C. A GLP-1/GIP Dual Receptor Agonist DA4-JC Effectively Attenuates Cognitive Impairment and Pathology in the APP/PS1/Tau Model of Alzheimer's Disease. J Alzheimers Dis 2021. [PMID: 34366339 DOI: 10.3233/JAD-210256] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
22 Simó R, Bogdanov P, Ramos H, Huerta J, Simó-Servat O, Hernández C. Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes. Biomedicines 2021;9:926. [PMID: 34440130 DOI: 10.3390/biomedicines9080926] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
23 Yu TW, Lane HY, Lin CH. Novel Therapeutic Approaches for Alzheimer's Disease: An Updated Review. Int J Mol Sci 2021;22:8208. [PMID: 34360973 DOI: 10.3390/ijms22158208] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
24 Lv M, Xue G, Cheng H, Meng P, Lian X, Hölscher C, Li D. The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01. Brain Behav 2021;11:e2231. [PMID: 34125470 DOI: 10.1002/brb3.2231] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
25 Zhao J, Imai R, Ukon N, Shimoyama S, Tan C, Maejima Y, Omiya Y, Takahashi K, Nan G, Zhao S, Ito H, Shimomura K. Evaluation of Effect of Ninjin'yoeito on Regional Brain Glucose Metabolism by 18F-FDG Autoradiography With Insulin Loading in Aged Mice. Front Nutr 2021;8:657663. [PMID: 34055854 DOI: 10.3389/fnut.2021.657663] [Reference Citation Analysis]
26 Marzook A, Tomas A, Jones B. The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells. Front Endocrinol (Lausanne) 2021;12:678055. [PMID: 34040588 DOI: 10.3389/fendo.2021.678055] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
27 Hölscher C. Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders. Br J Pharmacol 2021. [PMID: 33900631 DOI: 10.1111/bph.15508] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 21.0] [Reference Citation Analysis]
28 Labandeira CM, Fraga-Bau A, Arias Ron D, Muñoz A, Alonso-Losada G, Koukoulis A, Romero-Lopez J, Rodriguez-Perez AI. Diabetes, insulin and new therapeutic strategies for Parkinson's disease: Focus on glucagon-like peptide-1 receptor agonists. Front Neuroendocrinol 2021;62:100914. [PMID: 33845041 DOI: 10.1016/j.yfrne.2021.100914] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
29 Zheng M, Wang P. Role of insulin receptor substance-1 modulating PI3K/Akt insulin signaling pathway in Alzheimer's disease. 3 Biotech 2021;11:179. [PMID: 33927970 DOI: 10.1007/s13205-021-02738-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
30 Girges C, Vijiaratnam N, Athauda D, Auld G, Gandhi S, Foltynie T. The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability. Drugs Aging 2021;38:355-73. [PMID: 33738783 DOI: 10.1007/s40266-021-00853-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
31 Wang V, Kuo TT, Huang EY, Ma KH, Chou YC, Fu ZY, Lai LW, Jung J, Choi HI, Choi DS, Li Y, Olson L, Greig NH, Hoffer BJ, Chen YH. Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease. ACS Pharmacol Transl Sci 2021;4:858-69. [PMID: 33860208 DOI: 10.1021/acsptsci.1c00013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
32 Victorino DB, Nejm M, Guimarães-Marques M, Scorza FA, Scorza CA. Repurposing GLP-1 Receptor Agonists for Parkinson's Disease: Current Evidence and Future Opportunities. Pharmaceut Med 2021;35:11-9. [PMID: 33409802 DOI: 10.1007/s40290-020-00374-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]